Despite a strong correlation between expression of ERα and a favorable response to endocrine therapy, 40–50% of patients with ERα+ breast cancer develop resistance or exhibit de novo resistance, and patients with luminal B and ERα+/PGR− breast cancer exhibit a poor response to tamoxifen [40]. Here, ESR1 is linked to breast cancer.